v3.26.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Reconciles Segment Direct Profit or Loss

The following table reconciles segment direct profit or loss to the Company’s consolidated results:

 

Three Months Ended
March 31,

 

(in thousands)

2026

 

 

2025

 

Research and development:

 

 

 

 

 

QTORIN rapamycin for microcystic LM

$

1,535

 

 

$

1,154

 

QTORIN rapamycin for microcystic LM - Government grant income

 

 

 

 

(127

)

QTORIN rapamycin for cutaneous VM

 

444

 

 

 

321

 

QTORIN CMC

 

1,828

 

 

 

785

 

Non-program specific and unallocated research and development expenses:

 

 

 

 

 

Salaries and stock-based compensation

 

3,190

 

 

 

1,322

 

Consultants

 

1,353

 

 

 

247

 

Other

 

984

 

 

 

372

 

Total research and development

$

9,334

 

 

$

4,074

 

General and administrative:

 

 

 

 

 

Salaries and stock-based compensation

$

3,282

 

 

$

1,453

 

Consultants

 

716

 

 

 

1,062

 

Other

 

1,523

 

 

 

1,282

 

Total general and administrative

$

5,521

 

 

$

3,797

 

Loss from operations

$

(14,855

)

 

$

(7,871

)